이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 신경내분비암에 대한 일반적인 화학요법(Temozolomide)에 대한 항암제 Olaparib의 추가 테스트

2026년 11월 11일 업데이트: National Cancer Institute (NCI)

진행성 갈색 세포종 및 부신경절종에 대해 Temozolomide 대 Temozolomide 및 Olaparib를 평가하는 전향적 다기관 2상 시험

This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To compare the progression-free survival (PFS) of patients with advanced pheochromocytoma and paraganglioma (APP) receiving temozolomide (dose dense) and olaparib to that of patients receiving temozolomide (pulse dose) alone.

SECONDARY OBJECTIVES:

I. To compare the overall survival (OS) of patients with APP receiving temozolomide (dose dense) and olaparib versus (vs.) temozolomide (pulse dose) alone.

II. To compare the objective response rate (ORR) associated with temozolomide (dose dense) and olaparib vs. temozolomide (pulse dose) alone in patients with APP.

III. To evaluate and compare the toxicity profile of temozolomide-based combinations (temozolomide [dose dense] and olaparib vs. temozolomide [pulse dose]) in patients with APP using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE.

OTHER OBJECTIVE:

I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.

EXPLORATORY OBJECTIVES:

I. To assess biochemical response: serum catecholamines and metanephrines; urine catecholamines and metanephrines.

II. To assess biomolecular markers associated with clinical outcome: germline succinyl dehydrogenase (SDH) mutations and tumor status of the repair enzyme methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive temozolomide orally (PO) once daily (QD) and olaparib PO twice daily (BID) on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with contrast or magnetic resonance imaging (MRI) throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.

ARM II: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.

Patients discontinuing treatment due to reasons other than disease progression are followed every 12 weeks until disease progression, then every 6 months until 5 years after registration. Patients discontinuing treatment due to disease progression are followed every 6 months for 5 years after registration.

연구 유형

중재적

등록 (추정된)

46

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alaska
      • Anchorage, Alaska, 미국, 98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, 미국, 99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, 미국, 99508
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, 미국, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, 미국, 99508
        • Anchorage Oncology Centre
      • Anchorage, Alaska, 미국, 99508
        • Katmai Oncology Group
      • Anchorage, Alaska, 미국, 99508
        • Providence Alaska Medical Center
      • Anchorage, Alaska, 미국, 99504
        • Anchorage Radiation Therapy Center
    • California
      • Burbank, California, 미국, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
    • Florida
      • Fort Lauderdale, Florida, 미국, 33308
        • Holy Cross Hospital
      • Gainesville, Florida, 미국, 32610
        • UF Health Cancer Institute - Gainesville
    • Idaho
      • Boise, Idaho, 미국, 83712
        • Saint Luke's Cancer Institute - Boise
      • Fruitland, Idaho, 미국, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, 미국, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, 미국, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Twin Falls, Idaho, 미국, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Bloomington, Illinois, 미국, 61704
        • Illinois CancerCare-Bloomington
      • Canton, Illinois, 미국, 61520
        • Illinois CancerCare-Canton
      • Carthage, Illinois, 미국, 62321
        • Illinois CancerCare-Carthage
      • Centralia, Illinois, 미국, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Comprehensive Cancer Center
      • Danville, Illinois, 미국, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, 미국, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Dixon, Illinois, 미국, 61021
        • Illinois CancerCare-Dixon
      • Effingham, Illinois, 미국, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, 미국, 62401
        • Carle Physician Group-Effingham
      • Eureka, Illinois, 미국, 61530
        • Illinois CancerCare-Eureka
      • Galesburg, Illinois, 미국, 61401
        • Illinois CancerCare-Galesburg
      • Kewanee, Illinois, 미국, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, 미국, 61455
        • Illinois CancerCare-Macomb
      • Mattoon, Illinois, 미국, 61938
        • Carle Physician Group-Mattoon/Charleston
      • New Lenox, Illinois, 미국, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • O'Fallon, Illinois, 미국, 62269
        • Cancer Care Center of O'Fallon
      • Orland Park, Illinois, 미국, 60462
        • University of Chicago Medicine-Orland Park
      • Ottawa, Illinois, 미국, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin, Illinois, 미국, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, 미국, 61615
        • Illinois CancerCare-Peoria
      • Peru, Illinois, 미국, 61354
        • Illinois CancerCare-Peru
      • Princeton, Illinois, 미국, 61356
        • Illinois CancerCare-Princeton
      • Urbana, Illinois, 미국, 61801
        • Carle Cancer Center
      • Washington, Illinois, 미국, 61571
        • Illinois CancerCare - Washington
    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Institutes of Health Clinical Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Dana-Farber Cancer Institute
      • Newton, Massachusetts, 미국, 02467
        • Dana-Farber Cancer Institute - Chestnut Hill
    • Michigan
      • Ann Arbor, Michigan, 미국, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brighton, Michigan, 미국, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Brighton, Michigan, 미국, 48114
        • Trinity Health Medical Center - Brighton
      • Canton, Michigan, 미국, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Canton, Michigan, 미국, 48188
        • Trinity Health Medical Center - Canton
      • Caro, Michigan, 미국, 48723
        • Caro Cancer Center
      • Chelsea, Michigan, 미국, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Chelsea, Michigan, 미국, 48118
        • Chelsea Hospital
      • Clarkston, Michigan, 미국, 48346
        • Hematology Oncology Consultants-Clarkston
      • Clarkston, Michigan, 미국, 48346
        • Newland Medical Associates-Clarkston
      • Detroit, Michigan, 미국, 48236
        • Henry Ford Health Saint John Hospital
      • East China Township, Michigan, 미국, 48054
        • Henry Ford River District Hospital
      • Flint, Michigan, 미국, 48503
        • Hurley Medical Center
      • Flint, Michigan, 미국, 48503
        • Genesee Hematology Oncology PC
      • Flint, Michigan, 미국, 48503
        • Genesys Hurley Cancer Institute
      • Flint, Michigan, 미국, 48503
        • Cancer Hematology Centers - Flint
      • Grosse Pointe Woods, Michigan, 미국, 48236
        • Henry Ford Saint John Hospital - Academic
      • Grosse Pointe Woods, Michigan, 미국, 48236
        • Henry Ford Saint John Hospital - Breast
      • Grosse Pointe Woods, Michigan, 미국, 48236
        • Henry Ford Saint John Hospital - Van Elslander
      • Lansing, Michigan, 미국, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, 미국, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Livonia, Michigan, 미국, 48154
        • Hope Cancer Clinic
      • Macomb, Michigan, 미국, 48044
        • Henry Ford Warren Hospital - Breast Macomb
      • Macomb, Michigan, 미국, 48044
        • Henry Ford Saint John Hospital - Macomb Medical
      • Marlette, Michigan, 미국, 48453
        • Saint Mary's Oncology/Hematology Associates of Marlette
      • Pontiac, Michigan, 미국, 48341
        • Hope Cancer Center
      • Pontiac, Michigan, 미국, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Pontiac, Michigan, 미국, 48341
        • Michigan Healthcare Professionals Pontiac
      • Pontiac, Michigan, 미국, 48341
        • Trinity Health IHA Medical Group-Alice Gustafson Center
      • Rochester Hills, Michigan, 미국, 48309
        • Henry Ford Rochester Hospital
      • Saginaw, Michigan, 미국, 48604
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, 미국, 48601
        • MyMichigan Medical Center Saginaw
      • Sterling Heights, Michigan, 미국, 48312
        • Bhadresh Nayak MD PC-Sterling Heights
      • Tawas City, Michigan, 미국, 48764
        • MyMichigan Medical Center Tawas
      • Warren, Michigan, 미국, 48088
        • Advanced Breast Care Center PLLC
      • Warren, Michigan, 미국, 48093
        • Macomb Hematology Oncology PC
      • Warren, Michigan, 미국, 48093
        • Henry Ford Madison Heights Hospital - Breast
      • Warren, Michigan, 미국, 48093
        • Henry Ford Health Warren Hospital
      • Warren, Michigan, 미국, 48093
        • Henry Ford Warren Hospital - GLCMS
      • West Branch, Michigan, 미국, 48661
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, 미국, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
      • Ypsilanti, Michigan, 미국, 48106
        • Huron Gastroenterology PC
    • Minnesota
      • Burnsville, Minnesota, 미국, 55337
        • Fairview Ridges Hospital
      • Burnsville, Minnesota, 미국, 55337
        • Minnesota Oncology - Burnsville
      • Cambridge, Minnesota, 미국, 55008
        • Cambridge Medical Center
      • Coon Rapids, Minnesota, 미국, 55433
        • Mercy Hospital
      • Edina, Minnesota, 미국, 55435
        • Fairview Southdale Hospital
      • Fridley, Minnesota, 미국, 55432
        • Unity Hospital
      • Maple Grove, Minnesota, 미국, 55369
        • Fairview Clinics and Surgery Center Maple Grove
      • Maplewood, Minnesota, 미국, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, 미국, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, 미국, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, 미국, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, 미국, 55454
        • Health Partners Inc
      • Monticello, Minnesota, 미국, 55362
        • Monticello Cancer Center
      • New Ulm, Minnesota, 미국, 56073
        • New Ulm Medical Center
      • Princeton, Minnesota, 미국, 55371
        • Fairview Northland Medical Center
      • Robbinsdale, Minnesota, 미국, 55422
        • North Memorial Medical Health Center
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic in Rochester
      • Saint Louis Park, Minnesota, 미국, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, 미국, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, 미국, 55102
        • United Hospital
      • Shakopee, Minnesota, 미국, 55379
        • Saint Francis Regional Medical Center
      • Stillwater, Minnesota, 미국, 55082
        • Lakeview Hospital
      • Waconia, Minnesota, 미국, 55387
        • Ridgeview Medical Center
      • Willmar, Minnesota, 미국, 56201
        • Rice Memorial Hospital
      • Woodbury, Minnesota, 미국, 55125
        • Minnesota Oncology Hematology PA-Woodbury
      • Wyoming, Minnesota, 미국, 55092
        • Fairview Lakes Medical Center
    • Missouri
      • Cape Girardeau, Missouri, 미국, 63703
        • Saint Francis Medical Center
    • Montana
      • Missoula, Montana, 미국, 59802
        • Saint Patrick Hospital - Community Hospital
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • Memorial Sloan Kettering Basking Ridge
      • Middletown, New Jersey, 미국, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, 미국, 07645
        • Memorial Sloan Kettering Bergen
    • New York
      • Albany, New York, 미국, 12208
        • Albany Medical Center
      • Commack, New York, 미국, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, 미국, 10604
        • Memorial Sloan Kettering Westchester
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
      • Uniondale, New York, 미국, 11553
        • Memorial Sloan Kettering Nassau
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
    • Oklahoma
      • Lawton, Oklahoma, 미국, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Bend, Oregon, 미국, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, 미국, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, 미국, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Coos Bay, Oregon, 미국, 97420
        • Bay Area Hospital
      • Newberg, Oregon, 미국, 97132
        • Providence Newberg Medical Center
      • Oregon City, Oregon, 미국, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, 미국, 97239
        • Oregon Health and Science University
      • Portland, Oregon, 미국, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, 미국, 97225
        • Providence Saint Vincent Medical Center
      • Redmond, Oregon, 미국, 97756
        • Saint Charles Health System-Redmond
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Bethlehem, Pennsylvania, 미국, 18017
        • Lehigh Valley Hospital - Muhlenberg
      • East Stroudsburg, Pennsylvania, 미국, 18301
        • Pocono Medical Center
      • Hazleton, Pennsylvania, 미국, 18201
        • Lehigh Valley Hospital-Hazleton
    • Texas
      • Austin, Texas, 미국, 78723
        • Dell Children's Medical Center of Central Texas
    • Utah
      • Farmington, Utah, 미국, 84025
        • Farmington Health Center
      • Salt Lake City, Utah, 미국, 84112
        • Huntsman Cancer Institute/University of Utah
      • Salt Lake City, Utah, 미국, 84106
        • University of Utah Sugarhouse Health Center
    • Virginia
      • Charlottesville, Virginia, 미국, 22908
        • University of Virginia Cancer Center
    • Washington
      • Aberdeen, Washington, 미국, 98520
        • Providence Regional Cancer System-Aberdeen
      • Bellingham, Washington, 미국, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Centralia, Washington, 미국, 98531
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, 미국, 98026
        • Swedish Cancer Institute-Edmonds
      • Everett, Washington, 미국, 98201
        • Providence Regional Cancer Partnership
      • Issaquah, Washington, 미국, 98029
        • Swedish Cancer Institute-Issaquah
      • Kennewick, Washington, 미국, 99336
        • Kadlec Clinic Hematology and Oncology
      • Lacey, Washington, 미국, 98503
        • Providence Regional Cancer System-Lacey
      • Longview, Washington, 미국, 98632
        • PeaceHealth Saint John Medical Center
      • Seattle, Washington, 미국, 98107
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, 미국, 98122
        • Swedish Medical Center-First Hill
      • Seattle, Washington, 미국, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, 미국, 98122-5711
        • Swedish Medical Center-Cherry Hill
      • Sedro-Woolley, Washington, 미국, 98284
        • PeaceHealth United General Medical Center
      • Shelton, Washington, 미국, 98584
        • Providence Regional Cancer System-Shelton
      • Vancouver, Washington, 미국, 98664
        • PeaceHealth Southwest Medical Center
      • Walla Walla, Washington, 미국, 99362
        • Providence Saint Mary Regional Cancer Center
      • Yelm, Washington, 미국, 98597
        • Providence Regional Cancer System-Yelm
    • Wisconsin
      • New Richmond, Wisconsin, 미국, 54017
        • Cancer Center of Western Wisconsin

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

12년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Documentation of disease

    • Histologic documentation: Histologically-proven advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma
    • Stage: Advanced (metastatic or unresectable primary) disease
    • Tumor site: Histologically-proven pheochromocytoma or paraganglioma
    • Radiographic evaluation: Radiographic evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in the 12 months prior to registration
  • Measurable disease

    • Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes). Non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
  • Prior treatment with other somatostatin analog, chemotherapy, radiotherapy (including peptide radionuclide receptor therapy [PRRT]), or surgery must be completed >= 28 days prior to registration. Patients must have recovered from any effects of any major surgery prior to registration

  • Prior treatment with radiolabeled metaiodobenzylguanidine (MIBG) must be completed >= 12 weeks prior to registration and lifetime cumulative 131I-MIBG dose must be < 1000 MBq kg^-1 (36 mCi kg^-1)

  • Prior treatment with antibiotics must be completed >= 7 days prior to registration

  • No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor

  • No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)

  • Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required

  • Contraception

    • Therapy utilized in this trial is associated with medium/high fetal risk
    • Women of childbearing potential and their partners, who are sexually active, must agree to use two highly effective forms of contraception in combination. This should be started from the time of registration and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse
    • Male patients must use a condom during treatment and for 3 months after the last dose of study drug(s) when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking study drug(s) and for 3 months following the last dose of study drug(s)
  • Age >= 12 years

  • Eastern Cooperative Oncology Group (ECOG) Patients ≥ 18 years of age: Performance status: 0-2

    • Patients < 16 years of age: Lansky ≥ 50%
    • Patients 16 to < 18 years of age: Karnofsky ≥ 50%
    • Patients ≥ 18 years of age: ECOG performance status ≤ 2
  • Absolute neutrophil count >= 1,500/mm^3

  • Platelet count >= 100,000/mm^3

  • Hemoglobin >= 10 mg/dL if prior radionuclide therapy Hemoglobin >= 8 mg/dL if no prior radionuclide therapy

    • In the absence of transfusion within the previous 24 hours. Radionuclide therapy includes PRRT or MIBG
  • Total bilirubin =< 1.5 x upper limit of normal (ULN)

    • Except in the case of Gilbert's syndrome, then total bilirubin must be =< 3.0 x ULN
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN

  • Creatinine < 1.5 x ULN OR calculated (calc.) creatinine clearance > 50 mL/min

    • Calculated by Cockcroft-Gault equation

    • By Cockcroft-Gault equation. Alternatively, for patients < 18 years of age, maximum serum creatinine ≤ the below age-sex-specific norms:

      • Age 12 years: Male 1.2; female 1.2
      • Age 13 to < 16 years: Male 1.5; female 1.4
      • Age 16 to < 18 years: Male 1.7; female 1.4
  • No indication of uncontrolled, potentially reversible cardiac condition(s) as determined by investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's formula-corrected QT interval [QTcF] prolongation > 500 msec, electrolyte disturbances, etc.) and no known congenital long QT syndrome

  • No extensive bilateral lung disease or pneumonitis

  • No abnormal organ or bone marrow function =< 28 days prior to registration

  • Patients with human immunodeficiency virus (HIV) positivity are allowed if CD4 count > 250 cells/uL and they have an undetectable HIV viral load within 6 months of registration

  • No active infection

  • No history of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia

  • No known gastrointestinal condition(s) that might predispose for drug intolerability or poor drug absorption

  • No known medical condition causing an inability to swallow oral formulations of agents

  • No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PARP inhibitors

  • Concurrent use of combination antiretroviral therapy (ART) is not permitted

  • Chronic concomitant treatment with strong or moderate CYP3A4 inducers or inhibitors is not allowed. Patients must discontinue the agent(s) >= 21 days prior to registration; enzalutamide and/or phenobarbital must be discontinued >= 5 weeks prior to registration

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm I (temozolomide, olaparib)

Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given PO

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Given PO

다른 이름들:
  • 린파자
  • AZD2281
  • AZD-2281
  • KU-0059436
  • PARP 억제제 AZD2281
  • KU0059436
  • 올라닙
  • 올라파릭스
  • 쿠 0059436

Undergo CT with contrast

다른 이름들:
  • 조영 증강 컴퓨터 단층 촬영
  • 대비 강화 CT 스캔
  • 대비가 있는 CT 스캔
  • 대비가 있는 CT
활성 비교기: Arm II (temozolomide)

Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given PO

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo CT with contrast

다른 이름들:
  • 조영 증강 컴퓨터 단층 촬영
  • 대비 강화 CT 스캔
  • 대비가 있는 CT 스캔
  • 대비가 있는 CT

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free survival (PFS)
기간: From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years

Will be compared between treatment arms using the un-stratified log-rank test at one-sided level of 0.11 and the p-value will be used for decision making. The hazard ratio will be estimated using a Cox proportional hazards model and the 95% confidence interval for the hazard ratio will be provided. Results from a stratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer-Crowley methodology will be used to construct the 95% confidence interval for the median PFS for each treatment arm.

From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Overall survival (OS)
기간: From randomization to death due to any cause, assessed up to 5 years

Patients who are alive will be censored at last follow-up. The distribution of survival time will be estimated using the method of Kaplan-Meier. OS will be compared between treatment arms using the log-rank test. OS medians, survival rates and hazard ratio will be estimated along with 95% confidence intervals.

From randomization to death due to any cause, assessed up to 5 years
Objective response
기간: Up to 5 years

Will be assessed by RECIST version 1.1 criteria. Will be estimated using objective response rate where objective response rate is defined as the number of evaluable patients achieving a response (partial response or complete response per RECIST version 1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% binomial confidence intervals.

Up to 5 years
Incidence of adverse events
기간: Up to 5 years

Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The term toxicity is defined as adverse events that are classified as possibly, probably, or definitely related to study treatment. Toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events standard toxicity grading. Similarly, scores (0-4) and the maximum score for each Patient-Reported Outcomes-CTCAE item will be recorded for each patient.

Up to 5 years

기타 결과 측정

결과 측정
측정값 설명
기간
Biochemical response
기간: Up to 5 years

Levels of chromogranin A, urine and/or plasma catecholamines and metanephrines may predict response to therapy. The proportion of patients with a biochemical response of partial response or better, as determined by plasma and/or urine catecholamines and metanephrines, will be calculated, and a 95% confidence interval will be placed on this proportion. For each factor, we will calculate the mean +/- standard deviation, minimum, maximum, and quartiles; in addition, we will generate box and whisker plot.

Up to 5 years
Biomolecular markers associated with clinical outcome
기간: Up to 5 years

Will analyze for methyltransferase (MGMT) methylation expression in archival tumors and correlate with the radiographic response rate in metastatic pheochromocytoma/paraganglioma. This is hypothesis generated box and whisker plot.

Up to 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Jaydira Del Rivero, Alliance for Clinical Trials in Oncology

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 3월 17일

기본 완료 (추정된)

2028년 3월 1일

연구 완료 (추정된)

2028년 3월 1일

연구 등록 날짜

최초 제출

2020년 5월 19일

QC 기준을 충족하는 최초 제출

2020년 5월 19일

처음 게시됨 (실제)

2020년 5월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다